Sponsor of the Day:
Jerkmate
https://www.biopharmaglobal.com/2022/08/15/ionis-announces-that-fda-accepts-new-drug-application-and-grants-priority-review-of-tofersen-for-a-rare-genetic-form-of-als/
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a...
Aug 15, 2022 - CARLSBAD, Calif., July 26, 2022 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has...
new drug applicationgrants priority reviewionisannouncesfda
https://www.takeda.com/newsroom/newsreleases/2026/nda-rusfertide/
FDA Accepts NDA and Grants Priority Review for Rusfertide
Takeda and Protagonist announce U.S. FDA acceptance and grants priority review for rusfertide new drug application for adults with polycythemia vera (PV)
grants priority reviewfdaacceptsnda
https://www.takeda.com/newsroom/newsreleases/2026/fda-accepts-nda-priority-review-oveporexton-narcolepsy-type-1/
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for...
The FDA has accepted Takeda’s NDA and granted Priority Review for Oveporexton (TAK‑861), a potential first‑in‑class treatment for Narcolepsy Type 1.
grants priority reviewdrug administrationaccepts newfoodapplication